0001104659-25-104529
SEC filingStrong top-line growth driven by iDose TR adoption partially offset by iStent headwinds from LCD restrictions, with gross margin improvement.
In Q3 2025, Glaukos reported net sales of $133.5M, up 38% from $96.7M in Q3 2024, driven primarily by strong U.S. glaucoma growth (+57%) as iDose TR adoption accelerated. Gross margin improved to 78% from 77%, aided by the favorable product mix toward higher-priced iDose TR. Operating expenses grew 23% but slower than revenue, resulting in operating loss improving to $16.4M from $24.7M. Net loss narrowed to $16.2M from $21.4M. For the nine-month period, net sales reached $364.3M (+31%), gross margin improved to 78% from 76%, and net loss improved to $54.0M from $112.8M, driven by operating leverage and non-operating income improvements.
U.S. glaucoma revenue surged 57% to $80.8M, with iDose TR contributing significantly. However, iStent volumes declined due to final LCD restrictions from five MACs, which limited combination MIGS procedures. International glaucoma grew 20% to $29.4M, benefiting from broad-based procedure volume growth in the UK, Japan, France, and Germany, with favorable currency impacts. Corneal health revenue increased 13% to $23.3M, with Photrexa pricing gains offset by MDRP rebates. The recent FDA approval of Epioxa (October 2025) is expected to disrupt the corneal franchise as the market transitions from Photrexa, with a controlled launch beginning Q1 2026.
Management's outlook focuses on expanding iDose TR reimbursement and utilization, with increasing MAC coverage and J-code adoption improving the physician payment process. The upcoming PDUFA date in January 2026 for iDose TR re-administration could broaden the addressable patient population. Epioxa launch in Q1 2026 will introduce a novel incision-free keratoconus treatment, potentially driving corneal health growth despite near-term disruption. The company also secured EU MDR certification for iStent products, enabling renewed commercial activity in Europe. Capital expenditure commitments, including an $80M+ Huntsville facility, indicate long-term investment in manufacturing capacity. However, risks include continued LCD impacts on iStent, tariff and government shutdown uncertainties, and potential payer coverage challenges for new products.
As of September 30, 2025, Glaukos holds a strong liquidity position with $98.2 million in cash and cash equivalents and $175.5 million in short-term investments (total $273.7 million). The company has no outstanding debt after redeeming all convertible senior notes in December 2024. Shareholders' equity stands at $769.5 million, up slightly from $766.9 million at year-end 2024. Inventory increased to $63.9 million, primarily due to raw material buildup for iDose TR.
The company has a significant purchase commitment under a supply agreement with Celanese Canada ULC for raw materials used in iDose TR. The agreement requires minimum compensation payments of $6.3 million over four years, with $4.9 million remaining as of September 30, 2025, recorded as an intangible asset. Additionally, Glaukos has operating and finance lease obligations totaling $36.9 million and $69.8 million, respectively, including options to extend. Contingent consideration related to the Mobius acquisition is valued at $9.1 million, potentially up to $80.0 million if net sales milestones are met.
Glaukos did not repurchase any shares or pay dividends during the period. Capital expenditures for the nine months ended September 30, 2025 were $4.8 million, primarily for property and equipment. The company also purchased real estate (Aliso Building) for $16.6 million, classified as an asset acquisition. Debt management saw full redemption of the remaining $57.5 million convertible notes in December 2024, leaving the company debt-free.
The company operates as a single segment: ophthalmic therapies. Revenue is disaggregated into two product categories: Glaucoma ($301.9 million for 9M 2025, 70% U.S.) and Corneal Health ($62.4 million, 88% U.S.). Total revenue grew 31% year-over-year, driven by iDose TR commercialization. International revenue contributed 27% of total, primarily from Glaucoma products.
Glaukos's operating cash flow (CFO) of -$21.6M for the nine months ended September 30, 2025 represents a significant improvement from -$61.8M in the prior year. The net loss of $54.0M was more than offset by $78.2M in non-cash adjustments, primarily stock-based compensation ($45.9M), depreciation and amortization ($25.9M), and a $17.4M inducement expense from note exchange in 2024. Working capital was a net use of $46.9M, driven largely by a $42.8M increase in accounts receivable, indicating potential collection challenges or sales growth. Inventory burn was moderate at $3.7M.
Capital expenditure (capex) of $4.8M was stable year-over-year, representing a modest 2.2% of revenue (implied). The company did not repurchase shares or pay dividends, focusing on investing in short-term investments and acquisitions. Free cash flow (not stated) would be approximately -$26.4M after capex, but the company's cash balance remains healthy at $102.1M.
Overall, cash flow quality improved, but negative CFO and high working capital needs warrant monitoring. The company's reliance on non-cash items and continued investment in growth suggests a focus on long-term value creation over near-term cash generation.